Onimode Yetunde A, Ankrah Alfred, Adedapo Kayode S
Department of Nuclear Medicine, University College Hospital, Ibadan, Oyo State, Nigeria, West Africa; Department of Radiotherapy, University of Ibadan, Ibadan, Oyo State, Nigeria, West Africa.
Department of Nuclear Medicine, National Centre for Radiotherapy and Nuclear Medicine, Korle Bu Hospital, Accra, Ghana.
World J Nucl Med. 2016 Jan-Apr;15(1):24-9. doi: 10.4103/1450-1147.167585.
Hyperthyroidism continues to be a pressing public health concern in West Africa. Its prevalence in Africa has been quoted as 1.2%-9.9%, with Graves' disease as its most common cause. Radioiodine-131 (RAI) therapy of hyperthyroidism recently commenced in two government hospitals in Ghana and Nigeria. This is a retrospective analysis of consecutive patients treated with RAI for primary hyperthyroidism at the National Centre for Radiotherapy and Nuclear Medicine (NCRNM) from 2008-2013, and in the University College Hospital (UCH) from 2006-2013. Cure was defined as euthyroidism or hypothyroidism occurring at 6 months post-RAI. Data were analysed using SPSS version 21 and Epi Info version, categorical data were evaluated with the Chi-square test and Fisher's exact test. 94 patients were studied, aged 20-74 years; 78 were females, and 16 were males. 38 were Ghanaian and 56 Nigerian. The presence of thyroid-associated ophthalmopathy (TAO) made cure less likely (χ(2) P = 0.006, odds ratio = 0.118; 95% confidence interval, 0.027-0.518). Other factors assessed proved to be insignificant. Our findings suggest that hyperthyroid patients with TAO will benefit from a higher RAI dose than their counterparts without TAO.
甲状腺功能亢进症仍是西非一个紧迫的公共卫生问题。据报道，其在非洲的患病率为1.2%-9.9%，最常见的病因是格雷夫斯病。加纳和尼日利亚的两家政府医院最近开始采用放射性碘-131（RAI）治疗甲状腺功能亢进症。这是一项回顾性分析，研究对象为2008年至2013年在国家放射治疗与核医学中心（NCRNM）以及2006年至2013年在大学学院医院（UCH）接受RAI治疗原发性甲状腺功能亢进症的连续患者。治愈定义为RAI治疗后6个月出现甲状腺功能正常或甲状腺功能减退。使用SPSS 21版和Epi Info版进行数据分析，分类数据采用卡方检验和费舍尔精确检验进行评估。共研究了94例患者，年龄在20-74岁之间；其中78例为女性，16例为男性。38例为加纳人，56例为尼日利亚人。甲状腺相关眼病（TAO）的存在使治愈的可能性降低（χ(2) P = 0.006，比值比 = 0.118；95%置信区间，0.027-0.518）。评估的其他因素被证明无统计学意义。我们的研究结果表明，患有TAO的甲状腺功能亢进症患者比未患TAO的患者将从更高剂量的RAI治疗中获益。
